NewCardio Receives Notice of Allowance for Vital Patent for Cardio3KG(TM)

SANTA CLARA, Calif., Feb. 25 /PRNewswire-FirstCall/ -- NewCardio, Inc. (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent covering technology relating to NewCardio's Cardio3KG solution (formerly VisualECG or Visual3Dx). This represents the core patent for NewCardio's anticipated emergency/urgent care solution, Cardio3KG.  

The Cardio3KG solution is comprised of a set of algorithms and tools that provide a comprehensive method to assess cardiac electrical activity in time and space, and to extract additional 3-dimensional information from standard 12-lead ECG signals.  This may enable Cardio3KG to assess potentially fatal diseases and conditions, including acute coronary syndrome, with greater speed and accuracy than possible by standard ECG.

When issued, together with US patent 7,266,408, this will be NewCardio's second U.S. patent covering broad aspects of the Company's 3-D ECG platform technology and, particularly, specifics of Cardio3KG, the first solution targeted to take full advantage of this intellectual property.

"This action by the USPTO reinforces our continuing investment in and commitment to our novel cardiovascular diagnostic platform technology, which provides 3-D analysis of the heart's electrical activity," stated NewCardio's CEO, Branislav Vajdic, PhD.  "We believe the Cardio3KG solution will substantially improve the accuracy and timeliness of response and diagnosis for patients arriving at emergency departments with heart attack symptoms and related conditions. NewCardio's Cardio3KG will enable doctors to diagnose acute coronary syndromes more quickly and accurately than with traditional methods, possibly saving thousands of lives annually and reducing costs associated with unnecessary hospital admissions. We also believe Cardio3KG, along with QTinno™ and CardioBip™, represent important steps forward in validating our 3-D ECG platform's ability to improve cardiac diagnosis, clinical outcomes, and drug safety.  We are pleased that patent offices in both the US and Europe are acknowledging our proprietary claims to our core technologies."

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG).  NewCardio's three-dimensional ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect.  NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

SOURCE NewCardio, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED